A detailed history of Kbc Group Nv transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Kbc Group Nv holds 2,568 shares of RARE stock, worth $114,918. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,568
Previous 2,062 24.54%
Holding current value
$114,918
Previous $85,000 68.24%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$40.21 - $59.36 $20,346 - $30,036
506 Added 24.54%
2,568 $143,000
Q2 2024

Jul 17, 2024

BUY
$37.42 - $51.61 $17,886 - $24,669
478 Added 30.18%
2,062 $85,000
Q4 2023

Feb 13, 2024

BUY
$31.73 - $49.19 $50,260 - $77,916
1,584 New
1,584 $76,000

Others Institutions Holding RARE

About Ultragenyx Pharmaceutical Inc.


  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $3.13B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track This Portfolio

Track Kbc Group Nv Portfolio

Follow Kbc Group Nv and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kbc Group Nv, based on Form 13F filings with the SEC.

News

Stay updated on Kbc Group Nv with notifications on news.